“We wanted to personally thank you for your continued generosity to support research through the Judith Graham Pool (JGP) research fellowship program. We cannot emphasize strongly enough how important your support is to the continued success of our JGP fellows and to the advancement of the innovative science they are pioneering. Your support directly impacts people living with inheritable blood disorders by accelerating the cutting- edge science that is revolutionizing treatments and health care. We are truly grateful for your partnership and commitment to advancing research and the careers of the promising researchers that you support. Today’s support is making tomorrow’s medicines a reality right now. Supporting the JGP is so critical to ensuring that innovative science continues to advance, and that innovative scientists are able to launch their hematology careers. Your whole-hearted support for the mission and your enthusiastic engagement is equally critical to our collective success. I wanted to express my deepest gratitude for making me feel so incredibly welcomed into the organization and the community. I’ve truly found my home here!” ~Kevin Mills, NHF, CSO
BDASC’s Annual Meeting has taken place for 49 years and provides the South Carolina bleeding disorders community the opportunity to come together and network, learn, and enjoy the empowerment of education and support. The presentation of the Chapter’s Annual Awards are provided on Friday night; including our awarding of college scholarships, introducing new board members and celebrating those who have served. A keynote speaker presentation is always a highlight for attendees as we search hard to bring in the very best and most current information in bleeding disorders. A teen track is provided concurrently with our adult programming. The HELLO Conference allows for attendees to enjoy a learning environment with educational presentations and breakout sessions. We learned in 2020 that our online ZOOM platform (forced upon us by COVID-19) helped us reach a broader audience and provided the opportunity to bring those who have not been available to join the annual meeting due to distance, health, or age, the opportunity to gather together with us in unity. We will work to provide a hybrid meeting in 2022 and ask you to encourage your family and friends who are affected by bleeding disorders, or who just want to learn more, to register and attend virtually. Information on current and future treatment therapies and bleeding disorders services are made available during our exhibit hall experience. Registration is required with BDASC for attendance. All meals, sessions and childcare are included with hotel accommodation available for our traveling guests. The event is free of charge for BDASC members.
Registration information to join the online virtual sessions will be available closer to the meeting date.
Disclaimers: As with all BDASC meetings, your personal information is secured only with the chapter. No personal information gathered or used by BDASC during the event will be shared with outside parties or vendors. BDASC will endeavor to ensure that all online meetings are safe and secure to the best of our abilities. Registration information will be available in the Spring of 2022. We hope you will plan to join us!
Quick Agenda: (Additional information to come)
5:30pm – Friday Night Chapter Annual Meeting
9:00am – Saturday Sessions and Breakouts
5:30pm – Dinner wrap-up, Hotel Terrace
Kevin Mills, PhD, Chief Scientific Officer, National Hemophilia Foundation
Kevin Mills, PhD joined the National Hemophilia Foundation as chief scientific officer. A graduate of University of Colorado Boulder, MIT, and Harvard Medical School, Dr. Mills is responsible for overseeing NHF’s research strategy, including developing and expanding the foundation’s research capabilities, and setting research goals.
Dr. Mills brings more than 20 years of experience in biotechnology, hematology, and oncology to the role. In 2005, Dr. Mills joined the faculty at the Jackson Laboratory in Bar Harbor, Maine and led a laboratory focused on the biology of DNA repair in hematology and oncology. In 2012, he co-founded Cyteir Therapeutics, a biotechnology company developing and commercializing new therapies targeting DNA repair pathways. As Cyteir’s chief scientific officer, he led the team that brought a first-in-class RAD51 inhibitor into clinical trials. Dr. Mills subsequently joined Civetta Therapeutics as chief scientific officer.